(CYBN) – StreetInsider.com Reports
-
Cybin Inc (CYBN) Reports Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Cybin Inc (CYBN) Announces Grant of Additional U.S. Patent
-
Cybin Inc (CYBN) Closes $150M Share Placement
-
Cybin (CYBN) Initiates Phase 2 Proof-of-Concept Study of CYB004
-
Cybin Inc (CYBN) Reports Positive End-of-Phase 2 Meeting with FDA for CYB003
-
Cybin Inc (CYBN) Announces $150M Oversubscribed Private Placement at $0.43/sh
-
Cybin Inc (CYBN) Receives FDA Breakthrough Therapy Designation for CYB003
-
Cybin Inc. (CYBN) PT Lowered to $4 at Canaccord Genuity
-
Cybin Inc (CYBN) Granted Two Additional Patents in Japan in Support of DMT Program
-
Cybin Inc (CYBN) Granted FDA Clearance to Initiate a Phase 2a Study of CYB004
-
Cybin Inc (CYBN) Reports Positive Topline Data from Phase 1 Studies of CYB004 and SPL028
-
Cybin Inc (CYBN) Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
-
Cybin Inc (CYBN) Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
-
Cybin Inc (CYBN) Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder
-
Cybin Inc (CYBN) Announces $64M Units Offering
-
Cybin Inc (CYBN) Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
-
Cybin Inc (CYBN) Reports Positive Phase 2 Interim Data for CYB003
-
Cybin (CYBN) Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study
-
Cybin Inc (CYBN) Announces Grant of U.S. Patent Covering Deuterated Tryptamines
-
Cybin Inc (CYBN) to Acquire Small Pharma Inc.
-
Cybin Inc (CYBN) Renews $35M At-The-Market Equity Program
-
Cybin Inc (CYBN) Files $160M Mixed Shelf
-
Cybin Inc (CYBN) Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
-
Cybin Inc (CYBN) Granted US Patent Covering Proprietary Deuterated Psilocybin Analog in CYB003
-
Cybin Inc. (CYBN) PT Lowered to $4 at Oppenheimer
-
Cybin Inc (CYBN) Prices 24.26M Unit Offering at $0.34/sh
-
Cybin (CYBN) Announces Overnight Marketed Offering of Units
-
Cybin Inc (CYBN) Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
-
Cybin (CYBN) Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
-
Cybin Inc. (CYBN) PT Lowered to $4.50 at Oppenheimer
-
Cybin Inc. (CYBN) PT Lowered to $6 at Canaccord Genuity
-
Cybin Inc (CYBN) Announces Appointment of Aaron Bartlone as Chief Operating Officer
-
Cybin Inc (CYBN) Provides Corporate Update
-
Cybin Inc (CYBN) Announces EMBARK Open Access
-
Cybin Inc (CYBN) Announces Positive Data from CYB003 Phase 1/2a Trial
-
Cybin Inc (CYBN) to Cut 15% of Staff
-
Cybin Inc (CYBN) Announces Approval of First-in-Human Dosing of CYB004
-
Cybin Inc (CYBN) Highlights 2022 Accomplishments and Milestones
-
EF Hutton Starts Cybin Inc. (CYBN) at Buy
-
Cybin Inc. (CYBN) PT Lowered to $5.50 at Oppenheimer
-
Cybin Inc (CYBN) Provides Progress Update on its CYB004-E Phase 1 Trial
-
Cybin Inc (CYBN) and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Trial
-
Cybin Inc (CYBN) Granted FDA IND Clearance for its Phase 1/2a Clinical Trial of CYB003
-
Cybin Inc (CYBN) Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
-
Cybin Inc (CYBN) Acquires DMT Clinical Study from Entheon Biomedical
-
Cybin Inc. (CYBN) Announces Positive CYB004 PK Data - Oppenheimer
-
Cybin Inc (CYBN) Reports Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
-
Cybin Inc (CYBN) Achieves Additional Adelia Milestone
-
Cybin Inc (CYBN) Achieves Additional Adelia Milestone
-
Cybin Inc (CYBN) Awarded Notice of Allowance from USPTO for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
Back to CYBN Stock Lookup
